ISIrina M. Shevchuk

Irina M. Shevchuk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Irina M. Shevchuk has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cognizance and adherence to outpatient treatment in patients with prostate cancer after local treatment: multicenter study

    by Vladimir M. Perepukhov, K. M. Nyushko, B. Ya. Alekseev, I. M. Shevchuk, V. P. Aleshin, N. D. Movchan, O. A. Mailyan, R. L. Sugaipov, F. Sh. Mangutov, V. A. Biryukov, et al.

    Background. Prostate cancer is the most common cancer among men in Russia. Despite the successes of local treatment, the risk of biochemical recurrence (BR) persists and requires long-term monitoring of prostate-specific antigen (PSA). Patient compliance is a crucial factor of timely recurrence diagnosis. Aim. To evaluate cognizance and adherence to outpatient treatment in patients with local and locally advanced prostate cancer after local treatment in Russia. Materials and methods. Two-stage study was performed: survey of 22 oncologists from 18 centers and telephone survey of 2046 patients from 10 oncological centers who received local treatment in 2022. Original questionnaires were used. Statistical analysis was performed using the Statistica 10 software. Results. The majority of patients (99.2 %) are informed about the necessity of PSA level monitoring. However, 36.8 % did not know threshold PSA levels, 18.7 % did not undergo examination in a timely manner, and 4.3 % weren’t informed on the timeframes of monitoring. BR was diagnosed in 11.43 % of patients. Among them, in 16.2 % clinical recurrence was detected due to late BR diagnostics and belated visit to an oncologist. However, no statistically significant correlation between cognizance level, examination regularity with development of clinical recurrence was found (p 0.05). In 39.3 % of cases, treatment of prostate cancer due to diagnosed BR was delayed. Conclusion. Despite high general cognizance, significant deficit of practical knowledge and low adherence to regular monitoring were observed. To decrease the number of clinical recurrences developed due to delayed start of treatment after BR, comprehensive approach is necessary consisting of patient briefing and optimization of control methods at the medical facilities performing outpatient observation.

  • Open Access

    Avelumab maintenance therapy: effective standard of drug therapy of metastatic urothelial carcinoma

    by Irina M. Shevchuk, B. Ya. Alekseev, A. M. Ivanov, V. M. Perepukhov, K. M. Nyushko

    Background. Maintenance therapy with avelumab is the standard of care for patients with metastatic and locally advanced inoperable urothelial carcinoma who have not progressed with platinum-based chemotherapy. Between 2021 and 2024, 40 patients with metastatic and locally advanced inoperable urothelial carcinoma were treated at the N. A. Lopatkin Research Institute of Urology and Interventional Radiology and the Moscow Center for Immunotargeted Therapy. Their disease was confirmed to be controlled after 4–6 courses of platinum-based chemotherapy followed by maintenance therapy with avelumab. Aim. To evaluate the efficacy and tolerability of maintenance therapy with avelumab in metastatic urothelial cancer in real-world clinical practice. Materials and methods. The study included 11 women (27.5 %) and 29 men (72.5 %), aged 39 to 80 years. Mean age was 63.95 ± 10.9 years, median age was 65.5 (interquartile range 58.3–72.0 years). Patients were divided by primary tumor location as follows: bladder cancer (24 patients; 60 %), upper urinary tract cancer (14; 35 %), and multiple primary cancer (combined lesions) (2; 5 %). All patients received 4–6 cycles of platinum-based chemotherapy in the first line, with 28 (70 %) patients starting with the gemcitabine + cisplatin combination. Gemcitabine + cisplatin was used throughout treatment in 24 cases (60 %), gemcitabine + carboplatin (30.0 %) was used in 12 cases, and 4 (10 %) patients underwent a switch from gemcitabine + cisplatin to gemcitabine + carboplatin. Chemotherapy resulted in complete response in 6 patients (15 %), while the remaining patients experienced partial response (37.5 %) or stable disease (47.5 %). Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan–Meier method from the start of first-line chemotherapy. A subgroup analysis was performed to assess 12-, 24-, and 36-month PFS, taking into account prognostic factors. Results. The median follow-up was 23.3 months (6 to 54, interquartile range 27.1–45.8 months). Median PFS from the start of chemotherapy was 18 months (95 % confidence interval (CI) not reached – 11 months). PFS at 12, 24, and 36 months was 63.2 % (95 % CI 45.9–76.3), 49.3 % (95 % CI 32.5–64.0), and 45.8 % (95 % CI 29.1–61.0), respectively. PFS from the start of avelumab therapy was 14 months. Median OS was not reached at the time of analysis (95 % CI not reached – 22 months). OS at 12, 24, and 36 months was 88.9 % (95 % CI 73.1–95.7), 58.3 % (95 % CI 39.5–73.0), and 54.4 % (95 % CI 35.6–69.8), respectively. Better PFS rates were demonstrated in patients with a complete response to platinum-based therapy compared with those with partial response or stable disease, in patients receiving cisplatin compared with carboplatin, in patients with lymph node-only metastases compared with other metastatic sites, and in primary bladder tumors compared with upper urinary tract cancer. Immune-related adverse events were reported in 50 % of patients, but only in 7.5 % (n = 3) of cases did these lead to avelumab discontinuation. Therapy interruption occurred in 1 patient. Conclusion. Real-world clinical practice has demonstrated that maintenance therapy with avelumab is an effective strategy for long-term disease control in patients with metastatic and locally advanced inoperable urothelial cancer, with an acceptable immune-mediated toxicity profile.

  • Open Access

    Biosimilars in the practice of modern oncologist

    by I. M. Shevchuk, A. S. Kalpinskiy

    Currently, genetically engineered drugs are widely used in oncological clinical practice which has significantly increased treatment cost. One of the most effective ways to decrease cost is substitution of an innovative drug after patent expiration with a reproduced compound – biosimilar.In this article, a problem of biosimilars is actualized both worldwide and in Russia, characteristics of these products are described, and the path of the agents from the moment of reproduction through preclinical and clinical trials to introduction into real clinical practice is traced, examples of such trials are presented.The results of clinical trials of effectiveness and safety of Pembroria® in patients with various oncological pathologies are described in detail. The first data from the multicenter prospective post-marketing trial PERFECTION are presented demonstrating similar effectiveness and tolerability results for the biosimilar in a multicohort patient category compared to pembrolizumab molecule.Manufacturing of high-quality analogs and their introduction into clinical practice create a possibility to provide more patients in need with modern highly effective and safe drugs as well as increases effectiveness of the state healthcare system.

  • Open Access

    First experience of using Pembroria® medication in patients with disseminated renal cell carcinoma

    by I. M. Shevchuk, N. D. Movchan

    Background. According to the clinical guidelines from the leading Russian and international societies, treatment of patients with metastatic renal cell carcinoma is based on combination use of immune and targeted drugs. In December of 2022, the first Russian analogue of immune-oncological drug pembrolizumab with trade name Pembroria® was registered in Russia.Aim. To evaluate safety of the biosimilar, as well as register its effectiveness in the form of objective response estimation in accordance with the RECIST v.1.1 (Response Evaluation Criteria in Solid Tumors version 1.1) criteria. The article presents the results of the first experience of using Pembroria® in real clinical practice. Two clinical observations are presented demonstrating effectiveness and safety of the biosimilar.Materials and methods. At the clinic of the N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiology Center, 21 patients with clear cell renal cell carcinoma who did not previously receive systemic antitumor treatment underwent immunotarget therapy with Pembroria® and a targeted agent: lenvatinib (20 mg/day orally) or axitinib (10 mg/day orally).Results. The analysis of effectiveness considering short follow-up periods was performed in 18 patients. Median follow-up period was 6 (2–13) months and objective response rate was 50 %, in 28 % of cases stable disease was observed. Survival rates were not evaluated due to short observation time.Conclusion. Use of Pembroria® medication in patients with metastatic renal cell carcinoma in real clinical practice showed high objective response rate with acceptable toxicity level. No new, previously not described adverse events were registered during Pembroria® administration.

  • Open Access

    Efficacy of avelumab in the treatment of oncourological malignances. Results of registration studies and own experience

    by I. M. Shevchuk, K. M. Nyushko, B. Ya. Alekseev

    Background. In the JAVELIN Bladder 100 trial, 1st line maintenance with avelumab in combination with best supportive care significantly increased (9.2 months) overall survival compared to best supportive care in patients with locally advanced or metastatic urothelial cancer without progression after 1st line platinum-based chemotherapy: 29.7 months versus 20.5 months, respectively. Trial results led to inclusion of avelumab into the international guidelines as a standard of care with the highest level of evidence. Combined therapy with avelumab + axitinib in patients with previously untreated metastatic renal cell carcinoma showed higher progression-free survival and objective response rate compared to sunitinib in all IMDC (International Metastatic Renal Cancer Database Consortium) groups. Avelumab + axitinib is one of the immuno-oncology combinations with proven effectiveness for progression-free survival and objective response rate.Aim. To evaluate the effectiveness of avelumab in treatment of oncological urological diseases in routine clinical practice. Materials and methods. At the N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of the National Medical Research Radiology Center, 12 patients with locally advanced inoperable and metastatic urothelial cancer without progression after 1st line platinum-based chemotherapy in combination with gemcitabine received maintenance avelumab therapy. Median follow-up was 10 months. Primary endpoints were overall survival from the start of avelumab maintenance therapy and safety.Combined therapy with avelumab + axitinib was administered in 18 patients with metastatic renal cell carcinoma. Median follow-up was 9 (3-16) months. Overall survival, progression-free survival, response rate and safety in the overall population and according to IMDC groups were evaluated.Results. At data cut-off (March 2023) with median follow-up of 10 months, overall survival was 100 %, progression-free survival was 66.7 % (among patients who received more than 3 infusions - 100 %). Progression-free survival was higher in patients with tumors of the lower urinary tract compared to upper (72.5 % versus 60 %), complete response to induction platinum-based chemotherapy compared to partial response and stable disease (100 % versus 66.7 %) and presence of metastases in the lymph nodes only compared to visceral and bone metastases (100 % versus 66.7 %). Adverse events were observed in 4 (66.7 %) patients.Among 18 patients who received avelumab + axitinib, complete response was observed in 2 (11.1 %) patients, partial response in 6 (33.3 %) patients, stable disease in 9 (50 %) patients, disease progression in 1 (5.6 %) patient. Response to therapy was observed in patients of all prognosis groups; for large (5 cm) metastases in the lungs, soft tissues, lymph nodes and bones response was observed 3 months after treatment start. Overall survival for this follow-up duration was 100 %, progression-free survival was 96.4 ± 11.2 %. Adverse events were observed in 8 (44.4 %) patients, and in 6 (75 %) of them they were grade I—II and did not require infusion regimen correction or axitinib dose reduction.Conclusion. Avelumab maintenance therapy in the 1st line is the standard of care for patients with locally advanced and metastatic urothelial cancer without disease progression during 1st line platinum-based chemotherapy. Maintenance therapy allows to achieve better overall survival and progression-free survival irrespective of the choice of platinum regimen (cisplatin or carboplatin), response to platinum-based chemotherapy, number of chemotherapy cycles, tumor localization and advancement.Experience of the N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology confirms results of the JAVELIN Bladder 100 trial on the effectiveness of avelumab maintenance therapy in routine clinical practice. Combination drug therapy with avelumab and axitinib in patients with metastatic renal cell carcinoma is an effective and safe treatment method which allows to achieve fast objective response and has good tolerability in patients irrespective of IMDC group or metastasis location. Effectiveness and favorable safety profile of avelumab + axitinib combination were proven in the context of routine clinical practice.


  • Open Access

    New lenvatinib and pembrolizumab combination for metastatic renal cell carcinoma in 1st line drug treatment: comparative effectiveness and safety

    by B. Ya. Alekseev, I. M. Shevchuk

    Currently, combination immunotarget therapy is the treatment standard for patients with disseminated carcinoma of the renal parenchyma. Simultaneous inhibition of immune checkpoints of programmed cell death 1 (PD-1)/PD-L1 and VEGF/VEGFR signal transduction showed synergistic antitumor effect both in preclinical models and clinical practice.The article presents the results of phase III CLEAR (NCT02811861) trial.In the phase III CLEAR (NCT02811861) trial, 1069 patients with renal cell carcinoma with clear-cell component who previously did not receive systemic antitumor therapy were randomized 1:1:1 in groups of lenvatinib (20 mg/day per os) + pembrolizumab (200 mg intravenously once in 21 days), combination lenvatinib (18 mg/day per os) + everolimus (5 mg/day per os), and sunitinib (50 mg/day per os for 4 weeks with 2-week interval). The groups included 355, 357, and 357 patients respectively. Primary endpoint was progression-free survival (PFS) controlled by expertise of an independent central committee per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1). Additionally, patient overall survival (OS) and drug therapy tolerability were evaluated.Median PFS for lenvatinib with pembrolizumab was significantly higher than for sunitinib (23.9 months vs. 9.2 months; progression hazard ratio (HR) 0.39; 95 % confidence interval (CI) 0.32–0.49; p 0.001). Similar advantage in PFS was observed for lenvatinib with everolimus compared to sunitinib (median PFS 14.7 months vs. 9.2 months; HR 0.65; 95 % CI 0.53–0.8; p 0.001). OS also was higher for lenvatinib and pembrolizumab combination compared to sunitinib (death HR 0.66; 95 % CI 0.49–0.88; p = 0.005). No advantages in OS of lenvatinib and everolimus compared to sunitinib were detected (death HR 1.15; 95 % CI 0.88–1.5; p = 0.3). Frequency of grade III and higher adverse events among patients receiving lenvatinib + pembrolizumab, lenvatinib + everolimus, and sunitinib were 82.4, 83.1, and 71.8 %, respectively.Pembrolizumab + lenvatinib combination showed high effectiveness in 1st line treatment of renal cell carcinoma compared to sunitinib per PFS and OS values.


  • Open Access

    Risk factors for nephrolithiasis after radical cystectomy with intestinal plasty of the bladder.

    by M.Yu. Prosyannikov, Department of urolithiasis of N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation, N.V. Anokhin, D.A. Voytko, I.M. Shevchuk, T.S. Perepanova, O.V. Konstantinova, A.V. Sivkov, B.Ya. Alekseev, O.I. Apolikhin, et al.

    Introduction. Some studies have shown that urolithiasis is much more common in the group of patients who underwent radical cystectomy (RC) with intestinal plastic bladder than the average for the population. The aim of this study included the search of the frequency of urinary stones formation in patients after RC, depending on the type of intestinal plasty of the bladder and the type of urinary diversion, the analysis of risk factors for lithogenesis, the search for metabolic lithogenic disorders in this category of patients, and the assessment of the severity of the identified changes. Materials and methods. The work analyzed the data of 214 patients (169 men and 45 women) who were operated from 2008 to 2021 with a diagnosis of bladder cancer. Patients underwent RC with the formation of a hetero- or orthotopic ileoconduit. We analyzed the indicators of general urine analysis, biochemical blood test, bacteriological analysis of urine for flora, performed both before RC and in the late postoperative period. Also The results of ultrasound of the kidneys, bladder (reservoir), MSCT of the kidneys performed before RC and in the late postoperative period were studied. We selected 37 patients from the general group in random order, who prospectively underwent a biochemical blood test, a biochemical analysis of daily urine, and an assessment of the acid-base composition of venous blood. Statistical analysis was performed by calculating the relative risk, as well as calculating the t-test for independent groups using the computer program Statistica 10.0 (StatSoft USA). Results. Urinary stones of the upper urinary tract after RC, ortho- and heterotopic intestinal plastics of the bladder in the late postoperative period (more than 1 year) were diagnosed in 27 out of 214 patients (12.6%). The relative risk of urolithiasis in patients with pyelectasis before surgery is 3.87 times higher than in patients without changes in pelvicalyceal system at the preoperative stage (p=0.0004). In patients after RC with impaired renal function in stages III-V (GFR 60 ml/min (p=0.005). RC patients with a BMI >30 had a 2.431-fold higher risk of urinary stone formation than those with a BMI 7.0, diagnosed after surgical treatment (p=0.003). The relative risk of developing urolithiasis in patients with urine pH >7.0 detected before surgery is 4.85 (p 7.0 both before and after the operation, a decrease in the patient's GFR <60 ml / min and the presence of bacteriuria in the general analysis of urine after RC are the risk factors for the urolithiasis after RC, intestinal plasty of the bladder.


  • Open Access

    An observational multicenter study to evaluate the efficacy and safety of degarelix® for prostate cancer in routine clinical practice

    by K. M. Nyushko, B. Ya. Alekseev, V. M. Perepukhov, I. M. Shevchuk, V. A. Atduev, А. B. Zdobnikov, В. Б. Венскель, Е. V. Gurin, A. V. Eremenko, I. V. Belov, et al.

    Background. Prostate cancer (PCa) is an actual disease and a frequent oncological pathology in men. The main methods of radical treatment of patients with PCa are radical prostatectomy and radiation therapy. Radical prostatectomy s the most commonly used method of therapy in patients with localized PCa. Adjuvant hormone therapy after surgical treatment is the standard method of therapy in patients with the presence of lymph node metastases. At the same time, the standard approach of treatment of patients with metastatic PCa is combination therapy with medical (using of analogues or antagonists of luteinizing hormone-releasing hormone (LHRH) or surgical castration in combination with chemotherapy with docetaxel or new generation antiandrogens (enzalutamide or apalutamide)). Numerous studies have demonstrated the importance of achieving minimum testosterone levels at all stages of drug therapy in patients with PCa. It has also been shown that the use of LHRH analogues may be less effective to the use of LHRH antagonists (degarelix) in relation to the effectiveness of testosterone suppression. Thus, conducting a study aimed at studying the effectiveness of testosterone suppression using LHRH antagonists in various clinical situations and patient populations in real clinical practice is a very actual task.Aim. To evaluate the effectiveness and safety of castration therapy using degarelix in real clinical practice and in various clinical situations.Materials and methods. The object of an observational non-interventional study was 132 patients with PCa from 13 cancer centers of Russian Federation who were treated with LHRH antagonist degarelix. The study was non-interventional (observational), retrospectively-prospective, open multicenter and not randomized. In accordance with the design of the study, depending on the clinical situation, patients were divided into 3 groups: group A (n = 52; 39.4 %) – patients with primary metastatic hormone-sensitive PCa, who were shown to undergo combined drug treatment with castration therapy as one of the components; group B (n = 43; 32.6 %) – patients, who underwent combined hormonal and radiation treatment (ADT + radiation therapy); group C (n = 37; 28 %) – patients who underwent surgical treatment (radical prostatectomy with extended PLND) with the presence of metastases in the lymph nodes identified by the results of a morphological examination (pN1).Results and conclusion. As a result of a non-interventional observational study, high efficacy of androgen-deprivation therapy with the use of degarelix was demonstrated in relation to the suppression of testosterone and PSA in patients with primary metastatic and locally advanced PCa in various clinical situations, as well as low toxicity and satisfactory tolerability of this variant of hormonal treatment.

  • Open Access

    Prerequisites for lithogenesis after radical cystectomy: literature review

    by M. Yu. Prosyannikov, A. D. Kaprin, O. I. Apolikhin, B. Ya. Alekseev, A. V. Sivkov, I. M. Shevchuk, D. A. Voytko, N. V. Anokhin, М. Ю. Просянников

    Recently, there has been a worldwide increase in the incidence of bladder cancer. Improved morphological diagnostics, increased surgical activity and availability of chemotherapy allowed reducing the one-year mortality rate and increasing the five-year survival rate. However, at the same time, there was a struggle with complications arising after the treatment. According to the world and domestic literature, it is noted that with an increase in life expectancy in patients who underwent radical cystectomy with intestinal urine derivation, an almost twofold increase in the frequency of complications, including the formation of urinary stones, is recorded. Previous studies have shown that about 60 % of the stones identified in this category of patients are infectious, and 40 % formed because of metabolic disorders, which have their own characteristics with different types of urine derivation. In this work, we present an overview of the predisposition for stone formation in patients who underwent cystectomy for musculoinvasive bladder cancer, taking into account the type of urine derivation.

  • Surgical approaches to organ-preserving operations in patients with kidney cancer

    by B.Ya. Alekseev, Kirill M. Nyushko, I.M. Shevchuk, V.M. Perepukhov, V.P. Aleshin, S.A. Sergienko, A.S. Kalpinsky, V.A. Polyakov

    Рак почки - одна из наиболее значимых проблем в онкоурологии. Последние 10 лет наблюдается рост заболеваемости раком почки, при этом внедрение современных методов лучевой диагностики позволяет чаще выявлять заболевание на ранней стадии. Методом выбора при данной патологии на стадии Т1а является резекция почки. Следует отметить, что при данном хирургическом вмешательстве необходимо осуществление тщательного гемостаза, поскольку оно выполняется на органе с интенсивным кровообращением. Для обеспечения адекватного гемостаза во время резекции почки используют механические, физические и химические методы. В обзоре освещены различные методы и техники остановки кровотечения, применяемые при выполнении резекции почки. Приведены результаты крупных исследований, в которых оценивались различные способы гемостаза и снижение риска развития осложнений, ассоциированных с...